ADC Therapeutics (ADCT) Non-Current Debt (2020 - 2026)

ADC Therapeutics has disclosed Non-Current Debt across 7 years of filings, most recently posting $111.0 million for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $111.0 million, down 2.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $111.0 million (down 2.42% YoY), and the FY2025 annual result was $112.5 million, down 1.04% from the prior year.
• Non-Current Debt came in at $111.0 million for Q1 2026 at ADC Therapeutics, down from $112.5 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $115.2 million in Q3 2025 to a low of $109.7 million in Q4 2022.
• The 5-year median for Non-Current Debt is $113.6 million (2024), against an average of $113.1 million.
• Across the five-year window, Non-Current Debt advanced 25.89% in 2022 and declined 2.42% in 2026, its largest moves.
• ADC Therapeutics' Non-Current Debt stood at $109.7 million in 2022, then advanced by 2.72% to $112.7 million in 2023, then gained by 0.83% to $113.6 million in 2024, then slipped by 1.04% to $112.5 million in 2025, then decreased by 1.25% to $111.0 million in 2026.
• The last three Non-Current Debt figures came in at $111.0 million (Q1 2026), $112.5 million (Q4 2025), and $115.2 million (Q3 2025), per Business Quant data.